Cuál es el precio por GenSight Biologics S.A. (SIGHT)

Precio por GenSight Biologics S.A. (SIGHT) es de$0.12122506

Cuál es la capitalización de mercado por GenSight Biologics S.A. (SIGHT)

Capitalización de mercado por GenSight Biologics S.A. (SIGHT) es $19.76M

GenSight Biologics S.A. (SIGHT) Ratio P/S

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Año	Ratio P/S	Cambiar
Not enough data for the provided dates.

Año

Ratio P/S

Cambiar

Not enough data for the provided dates.

Empresa	Ratio P/S	Diferencia del ratio P/S	País
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Empresa

Ratio P/S

Diferencia del ratio P/S

País